PATENT CLAIM ANALYSIS

Application Number: 16068272
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "255050"]

Abstract:
Provided herein are compounds of the formula I: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.

Claim (Index 21):
A method of treating disorders associated with irregularities of the glutamatergic signal transmission, and the nervous system disorders mediated full or in part by mGlu5 receptors, which method comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound according to  claim 1  in free base or pharmaceutically acceptable salt form.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 95.0
- Lexical Diversity: 1.56522
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16091781', '15771920', '11360085', '11726807', '14344957']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8249223358146263
- 35 USC 102 Novelty (BERT): 0.5570936872617999
- Combined Prediction Score: 0.7981394709593437
- Mean Citation Score: 373.213428
- Max Citation Score: 444.10822
- Similarity Product: 331.25019843980425

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test